Ruijing Bio key facts
as of Oct 2026- Developer of molecular diagnosis technology designed for precision cancer medicine.
- Ruijing Bio is valued at approximately $109.1M as of Oct 2026 (last reported valuation).
- It has raised $44.0M; the latest was Later Stage VC ($13.7M) in May 2025.
- Notable investors include ZhenFund, Guotai Junan Innovation Investment, Shenzhen Yifeng Investment Management Enterprise, Prosperico Ventures, Rencent Capital — 7 tracked in total.
- Status: Privately Held (backing).
Ruijing Bio's last reported valuation, Apr 2022. Nothing priced has surfaced since.
- ·Watch Ruijing Bio: the Monday email on marks, rounds and moves
Ruijing Bio funding rounds
No funding rounds for Ruijing Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Ruijing Bio valuation
Ruijing Bio's last reported valuation was $109 million in Apr 2022. No priced round, secondary trade or fund mark has surfaced since.
Ruijing Bio investors
7 investors are on record for Ruijing Bio, including ZhenFund, Guotai Junan Innovation Investment, Shenzhen Yifeng Investment Management Enterprise and Prosperico Ventures.
About Ruijing Bio
Developer of molecular diagnosis technology designed for precision cancer medicine. The company offers digital PCR thermal cycler and Next Generation Sequencing machines for applications in thyroid cancer detection, thereby enabling medical professionals to deliver more accurate and earlier diagnoses to patients.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 200
- Website
- rigen-bio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.